1 / 1

ISAR-REACT 3

ISAR-REACT 3. Primary endpoint: death, MI, urgent target vessel revascularization, or in-hospital major bleeding was similar between the bivalirudin (8.3%) and UFH (8.7%) arms (p = 0.57) Bleeding significantly ↓ with bivalirudin compared with UFH: major (33%), minor (31%). (p = 0.57).

denton
Download Presentation

ISAR-REACT 3

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ISAR-REACT 3 Primary endpoint: death, MI, urgent target vessel revascularization, or in-hospital major bleeding was similar between the bivalirudin (8.3%) and UFH (8.7%) arms (p = 0.57) Bleeding significantly ↓ with bivalirudin compared with UFH: major (33%), minor (31%) (p = 0.57) (p = 0.008) 8.3 8.7 3.1 4.6 10 5 8 4 7 6 3 % % 5 2 4 3 2 1 0 0 Bivalirudin (n = 2,289) UFH (n = 2,281) Trial design:Troponin-negative patients undergoing PCI were randomized to either bivalirudin or unfractionated heparin (UFH), after pretreatment with 600 mg of clopidogrel. Clinical outcomes were evaluated at 30 days. Results 9 Conclusions • Bivalirudin is not superior to UFH as adjunct anticoagulation therapy for troponin-negative patients undergoing PCI, who were pretreated with 600 mg of clopidogrel • Bleeding was significantly reduced with bivalirudin compared with UFH 1 Composite endpoint Major bleeding Presented by Dr. Adnan Kastrati at SCAI-ACC i2 Summit/ACC 2008

More Related